Transdermal buprenorphine in the treatment of chronic pain

Expert Review of Neurotherapeutics

Volumn 5, Issue 3, 2005, Pages 315-323

  Sittl, Reinhard ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cancer pain; Noncancer pain; Opioid analgesics; Transdermal buprenorphine

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; DRUG METABOLITE; NALOXONE; NORBUPRENORPHINE; OPIATE; TRAMADOL; UNCLASSIFIED DRUG;

ANALGESIA; APNEA; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; OPIOID INDUCED EMESIS; PATIENT SATISFACTION; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRURITUS; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SLEEP TIME; SWEATING; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, CUTANEOUS; BUPRENORPHINE; CHRONIC DISEASE; HUMANS; PAIN; PAIN MEASUREMENT;

EID: 18944380310     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.3.315     Document Type: Review

References (51)

1. Staats PS, Johnson RE. New perspectives on the pharmacology of opioids and their use in chronic pain. Prog. Anesthesiol. 16, 235-249 (2002).
2. Grossman SA, Benedetti C, Brock C et al. NCCN Practice Guidelines for Cancer Pain. NCCN Proceedings 14, 135-150 (2000).
3. Ferrell B, Casarett D, Epplin J et al. The management of persistent pain in older persons. J. Am. Geriatr. Soc. 50(Suppl. 6), S205-S224 (2002).
4. Welsh J, Copp K, Dunne J et al. Control of pain in patients with cancer. A national clinical guideline. Edinburgh (Scotland). Scottish Intercollegiate Guidelines Network, 2000, 1-6 (1996).
5. Masson AHB. Sublingual buprenorphine versus oral dihydrocodeine in postoperative pain. J. Int. Med. Res. 9, 506-510 (1981).
6. Hanks GW. The clinical usefulness of agonist-antagonist opioid analgesics in chronic pain. Drug Alcohol Depend. 20, 339-46 (1987).
7. Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 17, 81-119 (1979).
8. Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int. J. Clin. Pract. 133(Suppl.), 9-14 (2003).
9. Allan L, Hays H, Jensen NH et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br. Med. J. 322, 1154-1158 (2001).
10. Payne R, Mathias SD, Pasta DJ et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J. Clin. Oncol. 16, 1588-1593 (1998).
11. Grünenthal GmbH. Transtec Scientific Monograph. (2002).
12. Martin WR, Eades CG, Thompson JA et al. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197, 517-532 (1976).
13. Lewis JW. Buprenorphine. Drug Alcohol. Depend. 14, 363-372 (1985).
14. Cowan A, Doxey JC, Harry EJR. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol. 60, 547-554 (1977).
15. Leander JD. Buprenorphine is a potent κ-opioid receptor antagonist in pigeons and mice. Eur. J. Pharmacol. 151, 457-461 (1988).
16. Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60, 537-545 (1977).
17. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 63, 1999-2010 (2003).
18. Dunn JE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br. J. Pharmacol. 74, 627-633 (1981).
19. Tyers MB. A classification of opiate receptors that mediate antinociception in animals. Br. J. Pharmacol. 69, 503-512 (1980).
20. Budd K. High-dose buprenorphine for postoperative analgesia. Anaesthesia 36, 900-903 (1981).
21. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55, 569-580 (1994).
22. Dahan A, Bijl H, Romberg R et al. Full reversal of buprenorphine induced respiratory depression by naloxone. Eur. J. Anaesthesiology (2005) (In Press).
23. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin. Pharmacokinet. 37, 17-40 (1999).
24. Budd K. Buprenorphine: a review. Evidence Based Med. Prac. 1-24 (2002).
25. Böhme K. Buprenorphine in a transdermal therapeutic system - a new option. Clin. Rheumatol. 21(Suppl. 1), S13-S16 (2002).
26. Data on file. Grünenthal. (2003).
27. Sittl R. Buprenorphine transdermal patch: clinical expert report. Grünenthal, GmbH, Germany (2000).
28. Rance MJ, Shillingford JS. The role of the gut in the metabolism of strong analgesics. Biochem. Pharmacol. 25, 735-741 (1976).
29. Rance MJ, Shillingford JS. The metabolism of phenolic opiates by rat intestine. Xenobiotica 7(9), 529-536 (1997).
30. Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 60, 1953-1964 (1977).
31. Ohtani M, Kotaki H, Nishitateno K. Kinetics of resoiratory depression in rats induced by buprenorphine and its metabolite, norbuprenrophine. J. Pharmacol. Exp. Ther. 281(1), 428-433 (1984).
32. Filitz J, Sittl R, Griessinger N, Likar R, Koppert W. Pharmacokinetics of transdermal buprenorphine (Transtec®) in patients with renal insufficiency. Poster presented at EAPC in Aachen. J. Pain Symptom Manage. (2005) (In Press).
33. McQuay HJ, Moore RA, Bullingham RES. Buprenorphine kinetics. In: Advances in Pain Research and Therapy. Foley KM, Inturrisi CE (Eds). Raven Press, NY, USA, 271-278 (1986).
34. Moore RA, Sear JW, Baldwin D et al. Morphine kinetics during and after renal transplantation in man. Clin. Pharmacol. Ther. 35, 641-645 (1997).
35. Böhme K. Buprenorphine transdermal system (TDS) (delivery rates 35/52.5/70 μg/h) in comparison to sublingual buprenorphine in chronic pain patients. 1st Congress of the Research Network of the European Association for Palliative Care, December 7-9, Berlin, Germany (2000).
36. Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomized, double-blind, placebo-controlled study. Pain Clinic 15, 193-202 (2003).
37. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther. 25, 150-68 (2003).
38. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 26(11), 1808-1820 (2004).
39. Radbruch L. Buprenorphine TDS: use in daily practice, benefits for patients. Int. J. Clin. Pract. (Suppl. 13), 19-22 (2003).
40. Kopp M. Buprenorphine transdermal system (TDS) in an open long-term study with chronic pain patients. 1st Congress of the Research Network of the European Association for Palliative Care, December 7-9, Berlin, Germany (2000).
41. Vielvoye-Kerkmeer APE. Long-term treatment with buprenorphine TDS in patients with chronic pain. Eur. J. Palliat. Care 10(Suppl. 1), 17-19 (2003).
42. Liedgens H, Ritzdorf I. Efficacy and safety of transdermal buprenorphine demonstrated in a large chronic pain population. Schmerz 17(Suppl. 1), S104-S105 (2003).
43. Twycross RG. Opioid analgesics in cancer pain: current practice and controversies. Cancer Surveys 7, 29-53 (1988).
44. Atkinson RE, Schofield P, Mellor P. The efficacy in sequential use of buprenorphine and morphine in advanced cancer pain. In: Opioids in the Treatment of Cancer Pain. Doyle D (Ed.). Royal Society of Medicine Services, International Congress and Symposium Series. 146, 81-87 (2004).
45. Camba MA, The Opioid Study Group of the Spanish Pain Society. Transdermal buprenorphine for the management of nociceptive chronic pain. Rev. Soc. Esp. Dolor. (Suppl V), 22-30 (1990).
46. Rodriguez-Lopez MJ, The Opioid Study Group of the Spanish Pain Society. Transdermal buprenorphine in the management of neuropathic pain. Rev. Soc. Esp. Dolor. (Suppl. V), 11-21 (2004).
47. Muriel C, The Opioid Study Group of the Spanish Pain Society. Assessment of buprenorphine transdermal patch in patients with cancer pain. Rev. Soc. Esp. Dolor. (Suppl. V), 41-48 (2004).
48. Barutell C de, The Opioid Study Group of the Spanish Pain Society. Buprenorphine and tramadol. Rev. Soc. Esp. Dolor. (Suppl. V), 31-40 (2004).
49. Gonzalez-Escalada JR, The Opioid Study Group of the Spanish Pain Society. Use of buprenorphine and oral morphine in patients with chronic pain. Rev Soc Esp Dolor (Suppl. V), 3-10 (2004).
50. Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin. Pharmacol. Ther. 45, 66-71 (1989).
51. Knape JTA. Early respiratory depression resistant to naloxone following epidural buprenorphine. Anesthesiology 64, 382-384 (1986).